InMed stock soars after promising Alzheimer’s drug preclinical results
InMed Pharmaceuticals Inc. stock doubled on Tuesday following the announcement of promising preclinical data for its Alzheimer’s disease drug candidate INM-901.
The pharmaceutical company revealed that INM-901 significantly reduced inflammation in ex vivo models of neuroinflammation, supporting its potential as a therapeutic candidate for Alzheimer’s disease. The study demonstrated that the drug reduced pro-inflammatory cytokines and may directly impact neuroinflammation independent of amyloid beta or tau aggregation.
Key findings showed INM-901 significantly reduced levels of NLRP3 and IL-1β, two inflammasome markers implicated in Alzheimer’s disease pathogenesis. The treatment resulted in a dose-dependent and statistically significant reduction in several pro-inflammatory markers, including IL-6, IL-1β, KC/Gro, and IL-2.
"NLRP3-driven inflammation is recognized as a key contributor to neurodegenerative disease progression," said Dr. Eric Hsu, SVP of Preclinical Research & Development at InMed. "The data derived from this LPS-induced inflammation study further support our previous findings in the amyloid beta animal model following INM-901 treatment."
The company plans to advance INM-901 through additional preclinical studies, with IND-enabling studies to follow. InMed describes INM-901 as a proprietary small molecule drug candidate with potentially multiple mechanisms of action, including reduced neuroinflammation and improved neurite growth and neuronal function.
INM-901 demonstrates multiple pharmacological effects in preclinical studies, including neuroprotective effects, the ability to promote neurite outgrowth (which is important for brain cell communication), and a reduction in neuroinflammation.
The drug can be administered orally and achieve therapeutic levels in the brain comparable to those obtained through intraperitoneal injection, potentially offering advantages over currently approved products.
